Intelligence · Clinical Development
Pipeline search results
Programs matching “non-small-cell-lung-cancer” across our ClinicalTrials.gov index — phase, modality, sponsor, and trial IDs.
Quick answer
Showing 211 pipeline programs matching "non-small-cell-lung-cancer" from NovaPharmaNews Clinical Development Intelligence — phase, modality, sponsor, and ClinicalTrials.gov trial IDs.
Refine search
Search results
-
Oral immunonutrition
Hospital Authority, Hong Kong
Non Small Cell Lung Cancer
1 trial -
Paclitaxel
Cellectar Biosciences
Non Small Cell Lung Cancer
1 trial -
Pemetrexed
Eli Lilly and Company
Non-Small Cell Lung Cancer
2 trials -
Placebo
Hoffmann-La Roche
Non-Squamous Non-Small Cell Lung Cancer
1 trial -
Placebos
Jian Li
Advanced Non-small Cell Lung Cancer
1 trial -
REGN2810
Regeneron UK Limited
Non-small Cell Lung Cancer
1 trial -
REGN2810/ipi
Regeneron UK Limited
Non-small Cell Lung Cancer
1 trial -
Rilvegostomig
AstraZeneca
Non-small Cell Lung Cancer
1 trial -
SHR-A2009 ; Aumolertinib
Suzhou Ribo Life Science Co.
Non-small Cell Lung Cancer
1 trial -
SSGJ-707
Sunshine Guojian Pharmaceutical (Shanghai) Co.,
Advanced Non-Small Cell Lung Cancer
1 trial -
Sacituzumab tirumotecan
Merck KGaA, Darmstadt, Germany
Non-small Cell Lung Cancer (NSCLC)
2 trials -
Sacituzumab tirumotecan
Merck KGaA, Darmstadt, Germany
Non Small Cell Lung Cancer
1 trial -
Selpercatinib
Eli Lilly and Company
Non-Small Cell Lung Cancer
1 trial -
Sevabertinib
Bayer HealthCare AG
Advanced Non-small Cell Lung Cancer
1 trial -
Sigvotatug Vedotin
Pfizer
Non-Small Cell Lung Cancer
1 trial -
Standard of Care
AbbVie
Non-Squamous Non-Small Cell Lung Cancer
1 trial -
TAK-788
Takeda
Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
1 trial -
TCM
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Non-small Cell Lung Cancer
1 trial -
Telisotuzumab Adizutecan
AbbVie
Non-Small Cell Lung Cancer
1 trial -
Tislelizumab
BeiGene
Non-small Cell Lung Cancer
2 trials -
Tislelizumab
BEONE MEDICINES AUS PTY LTD
Non Small Cell Lung Cancer
4 trials -
Toripalimab
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Non Small Cell Lung Cancer
1 trial -
Trastuzumab Deruxtecan
Daiichi Sankyo
Non-small Cell Lung Cancer
1 trial -
Vandetanib
Sanofi Pasteur
Non Small Cell Lung Cancer
1 trial
Frequently asked questions
What is the Clinical Development Intelligence Platform?
It is NovaPharmaNews pipeline intelligence hub covering 20,548 clinical development programs — not just a directory. It includes phase distribution dashboards, therapeutic area overviews, NDA/BLA watchlists, upcoming readouts, company pipeline rankings, competitive landscape maps, and personalized watchlists.
How does this compare to Evaluate Pharma or Citeline?
Like Evaluate Pharma and Citeline Trialtrove, we index ClinicalTrials.gov programs by sponsor, phase, and indication. Our platform adds cross-links to NovaPharmaNews company profiles, drug INN pages, patents, and congress readout calendars — improving crawl depth and reducing orphan program pages.
Where does pipeline data come from?
Program records derive from ClinicalTrials.gov and link to sponsor company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment decisions. See our data sources page for attribution.
Can I follow a company or program for updates?
Yes — use the watchlist forms on this page to follow sponsors, individual programs, disease clusters, or therapeutic areas. Alerts use the same subscription infrastructure as our events intelligence hub.